Author:
Shi Vivian Y.,Bhutani Tina,Fonacier Luz,Deleuran Mette,Shumack Stephen,Valdez Hernan,Zhang Fan,Chan Gary L.,Cameron Michael C.,Yin Natalie C.
Funder
School of Public Health, University of California Berkeley
Pfizer
Les Laboratories Pierre Fabre
Novartis
Shire
Eli Lilly and Company
AbbVie
Reference30 articles.
1. Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases;Vazquez;J Med Chem,2018
2. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial;Simpson;Lancet,2020
3. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial;Silverberg;JAMA Dermatol,2020
4. Abrocitinib versus placebo or dupilumab for atopic dermatitis;Bieber;N Engl J Med,2021
5. Prescribing Information;Dupixent,2020
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献